PRESS RELEASE published on 09/03/2024 at 14:30, 1 year 8 months ago Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1 MHRA authorizes Moderna's updated COVID-19 vaccine targeting JN.1 variant. Available for NHS and private purchase in the UK. Follows WHO recommendation for JN.1 subvariants COVID-19 Vaccine Moderna JN.1 Variant MHRA Authorization Private Purchase
BRIEF published on 09/02/2024 at 13:05, 1 year 8 months ago Taiwan FDA Approves Moderna’s COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1 COVID-19 Vaccine Moderna Spikevax Taiwan FDA SARS-CoV-2 JN.1
BRIEF published on 09/02/2024 at 13:05, 1 year 8 months ago La FDA de Taïwan approuve le vaccin COVID-19 de Moderna ciblant la variante JN.1 du SRAS-CoV-2 Moderne Vaccin Contre Le Covid-19 Spikevax SARS-CoV-2 JN.1 FDA De Taïwan
PRESS RELEASE published on 09/02/2024 at 13:00, 1 year 8 months ago Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1 Moderna receives approval for updated COVID-19 vaccine formulation targeting SARS-CoV-2 variant JN.1 from Taiwan FDA. Regulatory decisions globally expected soon COVID-19 Vaccine Moderna Spikevax SARS-CoV-2 Variant Taiwan FDA
BRIEF published on 08/29/2024 at 14:05, 1 year 8 months ago Moderna Launches National Awareness Campaign to Help Drive COVID-19 Vaccination COVID-19 Moderna Vaccination Health Campaign Public Awareness
BRIEF published on 08/29/2024 at 14:05, 1 year 8 months ago Moderna lance une campagne nationale de sensibilisation pour favoriser la vaccination contre la COVID-19 Moderne COVID 19 Vaccination Campagne De Santé Sensibilisation Du Public
PRESS RELEASE published on 08/29/2024 at 14:00, 1 year 8 months ago Moderna Launches National Awareness Campaign to Help Drive COVID-19 Vaccination Moderna launches 'Do It For You & Them' campaign to drive vaccination rates in the U.S. and inform about COVID-19 risks & impact, updated vaccines available for KP.2 variant COVID-19 Moderna Awareness Campaign KP.2 Variant Vaccination Rates
BRIEF published on 08/23/2024 at 13:05, 1 year 8 months ago Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R) Public Health European Commission MRNA Technology RSV Vaccine Moderna Approval
BRIEF published on 08/23/2024 at 13:05, 1 year 8 months ago Moderna reçoit l'approbation de la Commission européenne pour son vaccin contre le VRS mRESVIA(R) Santé Publique Vaccin Contre Le VRS Commission Européenne Technologie De L'ARNm Approbation De Moderna
PRESS RELEASE published on 08/23/2024 at 13:00, 1 year 8 months ago Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R) Moderna receives European Commission approval for mRESVIA(R) (mRNA-1345) vaccine to fight RSV in adults aged 60+; significant breakthrough beyond COVID-19 European Commission Moderna Vaccine RSV MRESVIA
Published on 05/05/2026 at 01:59, 2 hours 19 minutes ago Tolmer Yields >100,000 g/t Silver Trial Gravity Concentrate
Published on 05/04/2026 at 23:55, 4 hours 23 minutes ago Avant Brands Announces Voting Results from Its 2026 Annual General and Special Meeting of Shareholders
Published on 05/04/2026 at 23:01, 5 hours 17 minutes ago Copper Road Announces Closing of Non-Brokered Private Placement
Published on 05/04/2026 at 23:00, 5 hours 18 minutes ago PJX Resources Adopting Semi-Annual Financial Reporting ("SAR")
Published on 05/04/2026 at 22:50, 5 hours 28 minutes ago IBC Advanced Alloys Announces Amendment of Existing Credit Facility
Published on 05/05/2026 at 02:42, 1 hour 36 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus secures strategic partnership with Boral to deliver one of Australia’s largest logistics precincts
Published on 05/05/2026 at 02:34, 1 hour 44 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: March 2026 quarter update and Macquarie Australia Conference Presentation
Published on 05/04/2026 at 21:05, 7 hours 13 minutes ago EQS-Adhoc: Brockhaus Technologies AG: Preliminary revenue for Q1 2026 of €47.9 million and adjusted EBITDA of €7.6 million; forecast for the continuing operations unchanged
Published on 05/04/2026 at 20:02, 8 hours 16 minutes ago EQS-Adhoc: Rheinmetall AG: Preliminary operating margin in line with market expectation; revenue below market expectation despite growth due to delays into Q2 – 2026 full-year forecast reaffirmed
Published on 05/04/2026 at 19:30, 8 hours 48 minutes ago Shareholders approve all proposals – Dr Annelise Lüscher Hämmerli and Urs Simeon elected to the Board of Directors
Published on 05/04/2026 at 20:57, 7 hours 21 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 05/04/2026 at 20:57, 7 hours 21 minutes ago Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 05/04/2026 at 20:06, 8 hours 12 minutes ago Avril 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Published on 05/04/2026 at 19:05, 9 hours 13 minutes ago CP -Mise en œuvre d’un contrat de liquidité avec INVEST SECURITIES
Published on 05/04/2026 at 18:19, 9 hours 59 minutes ago Covivio Hotels - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
